Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma

Mohammad-Reza Sedghipour, Ali Mostafaei, Yousef TaghaviNikoukari Ophthalmology University Hospital, Tabriz University of Medical Sciences, Tabriz, IranBackground: The purpose of this study was to assess the effect of bevacizumab in maintaining intraocular pressure lowered by trabeculectomy in refrac...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sedghipour MR, Mostafaei A, Taghavi Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/fa3dea984b954836aa23f9eb47322a3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fa3dea984b954836aa23f9eb47322a3d
record_format	dspace
spelling	oai:doaj.org-article:fa3dea984b954836aa23f9eb47322a3d2021-12-02T03:56:56ZLow-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma1177-54671177-5483https://doaj.org/article/fa3dea984b954836aa23f9eb47322a3d2011-06-01T00:00:00Zhttp://www.dovepress.com/low-dose-subconjunctival-bevacizumab-to-augment-trabeculectomy-for-gla-a7656https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Mohammad-Reza Sedghipour, Ali Mostafaei, Yousef TaghaviNikoukari Ophthalmology University Hospital, Tabriz University of Medical Sciences, Tabriz, IranBackground: The purpose of this study was to assess the effect of bevacizumab in maintaining intraocular pressure lowered by trabeculectomy in refractory open-angle glaucoma.Methods: Thirty-seven eyes from 37 patients referring to Nikoukari Ophthalmology University Hospital in Tabriz were enrolled in this randomized clinical trial. Seventeen patients were randomly assigned to receive bevacizumab augmentation after trabeculectomy, and 20 patients were assigned to a control group receiving a placebo injection of normal saline. Bevacizumab was injected subconjunctivally at a dose of 0.2 mg. Intraocular pressure was measured on eight occasions, ie, at baseline, 24 hours, 3 days, 7 days, 2 weeks, 1 month, 2 months, and 3 months after treatment.Results: Men constituted 81% of the participants, who were of mean age 67.5 years. Twenty-nine patients had secondary open-angle glaucoma, while eight patients had primary open-angle glaucoma. Intraocular pressure decreased from a mean of 28.4 mmHg at baseline to a mean of 12.1 mmHg during the first day and to 15.1 mmHg after 3 months. Adding bevacizumab to trabeculectomy was not found to affect intraocular pressure differently to placebo. Neither the results of repeated measurements analysis nor single comparison statistical tests were significant for a difference in efficacy of bevacizumab versus placebo.Conclusion: Subconjunctival bevacizumab 0.2 mg was not found to affect the trend in intraocular pressure more than placebo after trabeculectomy for open-angle glaucoma.Keywords: glaucoma, trabeculectomy, bevacizumab, antivascular endothelial growth factor agentsSedghipour MRMostafaei ATaghavi YDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 797-800 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Sedghipour MR Mostafaei A Taghavi Y Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma
description	Mohammad-Reza Sedghipour, Ali Mostafaei, Yousef TaghaviNikoukari Ophthalmology University Hospital, Tabriz University of Medical Sciences, Tabriz, IranBackground: The purpose of this study was to assess the effect of bevacizumab in maintaining intraocular pressure lowered by trabeculectomy in refractory open-angle glaucoma.Methods: Thirty-seven eyes from 37 patients referring to Nikoukari Ophthalmology University Hospital in Tabriz were enrolled in this randomized clinical trial. Seventeen patients were randomly assigned to receive bevacizumab augmentation after trabeculectomy, and 20 patients were assigned to a control group receiving a placebo injection of normal saline. Bevacizumab was injected subconjunctivally at a dose of 0.2 mg. Intraocular pressure was measured on eight occasions, ie, at baseline, 24 hours, 3 days, 7 days, 2 weeks, 1 month, 2 months, and 3 months after treatment.Results: Men constituted 81% of the participants, who were of mean age 67.5 years. Twenty-nine patients had secondary open-angle glaucoma, while eight patients had primary open-angle glaucoma. Intraocular pressure decreased from a mean of 28.4 mmHg at baseline to a mean of 12.1 mmHg during the first day and to 15.1 mmHg after 3 months. Adding bevacizumab to trabeculectomy was not found to affect intraocular pressure differently to placebo. Neither the results of repeated measurements analysis nor single comparison statistical tests were significant for a difference in efficacy of bevacizumab versus placebo.Conclusion: Subconjunctival bevacizumab 0.2 mg was not found to affect the trend in intraocular pressure more than placebo after trabeculectomy for open-angle glaucoma.Keywords: glaucoma, trabeculectomy, bevacizumab, antivascular endothelial growth factor agents
format	article
author	Sedghipour MR Mostafaei A Taghavi Y
author_facet	Sedghipour MR Mostafaei A Taghavi Y
author_sort	Sedghipour MR
title	Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma
title_short	Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma
title_full	Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma
title_fullStr	Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma
title_full_unstemmed	Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma
title_sort	low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/fa3dea984b954836aa23f9eb47322a3d
work_keys_str_mv	AT sedghipourmr lowdosesubconjunctivalbevacizumabtoaugmenttrabeculectomyforglaucoma AT mostafaeia lowdosesubconjunctivalbevacizumabtoaugmenttrabeculectomyforglaucoma AT taghaviy lowdosesubconjunctivalbevacizumabtoaugmenttrabeculectomyforglaucoma
_version_	1718401589587214336

Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma

Ejemplares similares